Protheragen Launches Intermediary Services for Biotechnology and Drug R&D Companies
As a provider of one-stop solution for early-stage drug projects, the New York-based company Protheragen recently announced to launch intermediary services, one of its most distinctive businesses, to connect biotechnology and drug R&D companies in an effort to bridge cooperation between the two.
Ever since its founding in Ronkonkoma, New York, 2009, Protheragen’s business range has been growing rapidly, which encompasses segments like equity investment and project incubation in addition to intermediary services, providing pharmaceutical licensing opportunities for clients who are interested. To ease communication and improve efficiency, offices have been established at different locations across China and the US.
“Relying on our internal database and connection network in the pharmaceutical industry and investment community, we decides to offer intermediary services for companies worldwide, such as assisting high-quality pharmaceutical R&D projects with fundraising, in-/out-licensing, and establishing co-development partnerships,” says Marketing Head of Protheragen. “Besides, we also make it easy and convenient to connect our clients with other incubators and accelerators in China and the US.”
Advantages of Protheragen’s Intermediary Services
- Over 10 years of accumulation of resources and networks in the pharmaceutical industry
- Closely engaged in venture capital and private equity investment communities
- Familiar with the latest trends in the biomedical and pharmaceutical industry in China and the US
What Does Protheragen Do in Intermediary Services?
Project collection
It collect the world’s best projects in biotechnology and new drug R&D that are interested to relocate in industrial parks.
Project transfer and collaboration
It searches and contacts the perfect licensees and partners for its clients.
Project fundraising
It collects investors and investment institutions for its clients.
Recruitment of talents
It can help recruiting top talents for clients' projects.
To learn more about Protheragen’s Intermediary Services as well as other capabilities, please visit https://www.protheragen.com/.
About Protheragen
After endeavors in the past decade and more, Protheragen grown to be a trust-worthy intermediary service provider. In order to bring out more for our clients, it has shifted to strategies that require constantly seeking of high-quality novel drug research and development programs, which are open to collaboration opportunities. Relying on strong industry resources and connections built up throughout the years, the company welcomes partnerships in areas of equity investment, intermediary service and project incubation.
Editor Details
-
Company:
- Protheragen
-
Name:
- Alice White
- Email:
-
Telephone:
- +16316197922
- Website: